Head-to-head · Value Score
CoreAge Rx vs REMEVi
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, REMEVi a 80. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$149/mo
Save ~89% vs brand-nameREMEVi
#67 · Grade B · Good Value
Est. first month
From $199/mo (starting dose, compounded)
Save ~85% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 80 — an est. $149/mo first month, with no teaser step-up baked in. REMEVi isn't out of it: Shoppers who want spanish-speaking patients wanting bilingual, LegitScript-certified compounded GLP-1.
CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | REMEVi |
|---|---|---|
| Value Score | 93 (A+) | 80 (B) |
| Est. first month | $149/mo | From $199/mo (starting dose, compounded) |
| Save vs brand-name | ~89% | ~85% |
| Semaglutide | $149/mo | From $199/mo (starting dose, compounded) |
| Tirzepatide | $349/mo | From $269/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | All 50 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
REMEVi
REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
Why it's a deal
- The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
- Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
- LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
- Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)
The fine print
- Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
- Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
- The specific compounding pharmacy is not named (described as 'NPI-verified')
- A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to REMEVi.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.